[Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen].
OBJECTIVE
To analyze drug resistance status of Pseudomonas aeruginosa in the two-drug regimens in laboratory and clinical settings for more appropriate application of antibiotics.


METHODS
The laboratory data of drug resistance rate of Pseudomonas aeruginosa identified with Biomerieux Vitek 32 system were collected. The clinical two-drug regimen data corresponding to anti-microbial sensitivity test were investigated, and the resistance rate of the clinical two-drug regimen was analyzed statistically.


RESULTS
The isolation rate of Pseudomonas aeruginosa with multi-drug resistance increased steadily in recent years, and the resistance rate to 6 widely used antibiotics increased by over 20%. Two Pseudomonas aeruginosa strains resistant to all the 6 drugs were identified in January 2004, and till June 2005, totally 18 panresistant strains had been isolated with dramatic increases in MIC value. In the clinical two-drug regimen, sulbactam/amikacin, sulbactam/ciprofloxacin, tazobactam/amikacin, and imipenem/amikacin still had low resistant rates.


CONCLUSIONS
Multi-drug resistance of Pseudomonas aeruginosa to the antibiotics is a serious problem. A two-drug regimen based on anti-microbial susceptibility test should be chosen.
Tian
Bi-wen
BW
Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Guangzhou 510120, China.
Yang
Ye-jian
YJ
Pang
Xue-yun
XY
D000583:Amikacin / Q000008:administration & dosage / Q000494:pharmacology; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D006801:Humans; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D013407:Sulbactam / Q000008:administration & dosage / Q000494:pharmacology; D000078142:Tazobactam
D002939:Ciprofloxacin; D000583:Amikacin; D010397:Penicillanic Acid; D013407:Sulbactam; D000078142:Tazobactam